BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug

Reuters12-18 13:37

** Alphamab Oncology 9966.HK rises 7.1% to HK$10.96; set for biggest one-day pct gain since October 2

** Stock hits highest since December 15 after three straight sessions of fall

** Company says its JSKN003 has been granted breakthrough therapy designation (BTD) by U.S. FDA to treat adults with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer

** Adds, "The grant of this BTD further demonstrates the international regulatory community's confidence in JSKN003's clinical potential and its importance as a novel therapeutic candidate"

** Grant of BTD based on pooled analysis of phase I clinical study in Australia and phase I/II clinical study in China

** YTD, stock surges 207.1%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592924931?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 13:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592924931","market":"us","top_or_hot":-1,"title":"BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug</title></head><body><p>** Alphamab Oncology <span>9966.HK</span> rises 7.1% to HK$10.96; set for biggest one-day pct gain since October 2</p><p>** Stock hits highest since December 15 after three straight sessions of fall</p><p>** Company says its JSKN003 has been granted breakthrough therapy designation (BTD) by U.S. FDA to treat adults with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer</p><p>** Adds, \"The grant of this BTD further demonstrates the international regulatory community's confidence in JSKN003's clinical potential and its importance as a novel therapeutic candidate\"</p><p>** Grant of BTD based on pooled analysis of phase I clinical study in Australia and phase I/II clinical study in China</p><p>** YTD, stock surges 207.1%</p><p> (Reporting by Donny Kwok)</p><p> ((donny.kwok@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 13:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug</title></head><body><p>** Alphamab Oncology <span>9966.HK</span> rises 7.1% to HK$10.96; set for biggest one-day pct gain since October 2</p><p>** Stock hits highest since December 15 after three straight sessions of fall</p><p>** Company says its JSKN003 has been granted breakthrough therapy designation (BTD) by U.S. FDA to treat adults with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer</p><p>** Adds, \"The grant of this BTD further demonstrates the international regulatory community's confidence in JSKN003's clinical potential and its importance as a novel therapeutic candidate\"</p><p>** Grant of BTD based on pooled analysis of phase I clinical study in Australia and phase I/II clinical study in China</p><p>** YTD, stock surges 207.1%</p><p> (Reporting by Donny Kwok)</p><p> ((donny.kwok@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL1N3XO05J:1","article_id":"2592924931","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592924931","pubTimestamp":1766036264,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug** Alphamab Oncology 9966.HK rises 7.1% to HK$10.96; set for biggest one-day pct gain since October 2** Stock hits highest since December 15 after three straight sessions of fall** Company says its JSKN003 has been granted breakthrough therapy designation  by U.S. FDA to treat adults with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer** Adds, \"The grant of this BTD further demonstrates the international regulatory community's confidence in JSKN003's clinical potential and its importance as a novel therapeutic candidate\"** Grant of BTD based on pooled analysis of phase I clinical study in Australia and phase I/II clinical study in China** YTD, stock surges 207.1%  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","09966":"康宁杰瑞制药-B"},"translate_title":"BUZZ-Alphamab Oncology因卵巢癌药物的进展而跃升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":0.9},"content_text":"BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug** Alphamab Oncology 9966.HK rises 7.1% to HK$10.96; set for biggest one-day pct gain since October 2** Stock hits highest since December 15 after three straight sessions of fall** Company says its JSKN003 has been granted breakthrough therapy designation (BTD) by U.S. FDA to treat adults with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer** Adds, \"The grant of this BTD further demonstrates the international regulatory community's confidence in JSKN003's clinical potential and its importance as a novel therapeutic candidate\"** Grant of BTD based on pooled analysis of phase I clinical study in Australia and phase I/II clinical study in China** YTD, stock surges 207.1% (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592924931","isCrawlerRequest":true}